Gynecomastia fat dissolving injections are increasingly sought by men looking to reduce excess chest tissue without surgery. However, understanding whether this treatment is appropriate depends critically on distinguishing true gynaecomastia — involving glandular breast tissue — from pseudogynaecomastia, which is caused by excess fat. Fat dissolving injections can only target adipose tissue, making accurate diagnosis essential before treatment. This article explains how these injections work, their regulatory status in the UK, associated risks, how they compare with other treatments, and what to look for when choosing a qualified practitioner.

What Is Gynaecomastia and What Causes It?

Gynaecomastia is the enlargement of glandular breast tissue in males due to an oestrogen–testosterone imbalance, and must be distinguished from pseudogynaecomastia (excess chest fat) as this determines appropriate treatment. Men aged 30 and over with an unexplained breast lump require urgent 2-week-wait referral under NICE NG12.

Gynaecomastia refers to the enlargement of glandular breast tissue in males, resulting from an imbalance between oestrogen and testosterone. It is a relatively common condition, with prevalence estimates varying widely across studies; peaks occur during puberty, middle age, and older adulthood. It is important to distinguish true gynaecomastia — which involves proliferation of glandular breast tissue — from pseudogynaecomastia, which is caused by an accumulation of fatty tissue in the chest area without glandular involvement. This distinction directly influences which treatment options are appropriate.

The causes of gynaecomastia are varied and can include:

• Hormonal changes during puberty or ageing

• Medications such as anabolic steroids, anti-androgens, some antidepressants, spironolactone, and certain antihypertensives

• Underlying health conditions including liver disease, hyperthyroidism, hypogonadism, and hormone-secreting tumours (including testicular and hCG-secreting tumours)

• Recreational drug use, including cannabis and alcohol

• Idiopathic causes, where no clear underlying reason is identified

A thorough clinical assessment is essential before pursuing any treatment. This should include a detailed medication and recreational drug history, testicular examination, and — where clinically indicated — blood tests such as liver function tests (LFTs), thyroid function tests (TFTs), morning testosterone, LH, FSH, prolactin, hCG, and oestradiol. Where clinical assessment alone cannot reliably differentiate glandular from fatty tissue, breast ultrasound may be helpful.

In line with NICE NG12 (Suspected cancer: recognition and referral), men aged 30 and over with an unexplained breast lump should be referred urgently via the 2-week-wait pathway to exclude malignancy. Urgent referral should also be considered for any person with suspicious skin or nipple changes, nipple discharge, or axillary lymphadenopathy, regardless of age. For men under 30 with a breast lump, non-urgent referral for assessment is appropriate if there is clinical uncertainty. For most men, however, gynaecomastia is benign and may resolve spontaneously, particularly in adolescents.

How Fat Dissolving Injections Work for Chest Tissue

Fat dissolving injections disrupt adipocyte membranes, causing fat cells to lyse and clear via the lymphatic system, but they have no effect on glandular tissue. They are therefore only suitable for pseudogynaecomastia, and chest use of Belkyra is off-label in the UK.

Fat dissolving injections most commonly contain deoxycholic acid (available in the UK and Europe under the brand name Belkyra) or phosphatidylcholine/deoxycholate (PCDC) compounds. These agents work by disrupting the cell membranes of adipocytes (fat cells), causing them to lyse and be gradually cleared via the lymphatic system.

Important regulatory note: In the UK, Belkyra (deoxycholic acid) holds a marketing authorisation only for the reduction of submental (under-chin) fat in adults. Any use for chest contouring is off-label. Many PCDC-based products available in the UK hold no UK marketing authorisation and are therefore unlicensed medicines. Patients should be made aware of this distinction and must receive explicit off-label consent before any chest treatment.

In the context of chest contouring, these injections are administered directly into localised fatty deposits in the pectoral region. Because no approved dosing schedule exists for chest use, practitioners cannot rely on a licensed posology for this indication. For reference, the Belkyra SmPC permits up to six treatment sessions for submental fat at intervals of at least four weeks; no equivalent approved regimen exists for the chest.

It is critically important to note that fat dissolving injections only target adipose (fatty) tissue. They have no effect on glandular breast tissue, which is the defining feature of true gynaecomastia. These injections are therefore most likely to benefit men with pseudogynaecomastia — excess chest fat without significant glandular involvement. Attempting to treat glandular gynaecomastia with fat dissolving injections is unlikely to produce satisfactory results. Where clinical assessment alone cannot confirm the tissue composition, ultrasound should be considered before proceeding.

Results can be long-lasting but vary between individuals; weight stability after treatment is important for maintaining outcomes. Swelling, bruising, tenderness, and temporary firmness in the treated area are expected following each session and typically resolve within one to two weeks.

Key contraindications and cautions (per the Belkyra SmPC) include: active infection at or near the injection site; caution in patients taking anticoagulants or with bleeding disorders; pregnancy and breast-feeding; and the critical requirement to administer only into subcutaneous tissue, avoiding intravascular or intramuscular injection.

Safety, Risks, and Regulatory Guidance in the UK

Belkyra is a UK prescription-only medicine licensed solely for submental fat; chest use is off-label, and many PCDC products are unlicensed. Risks include skin necrosis, nerve injury, infection, and scarring, and adverse reactions must be reported via the MHRA Yellow Card scheme.

In the United Kingdom, deoxycholic acid injection (Belkyra) is a prescription-only medicine (POM) and must be prescribed by a qualified prescriber following an appropriate clinical consultation. It is licensed only for submental fat reduction; chest use is off-label. Many PCDC-based 'fat dissolving' products available in the UK hold no UK marketing authorisation and are classed as unlicensed medicines. The Medicines and Healthcare products Regulatory Agency (MHRA) regulates the licensing and use of injectable medicines, and patients should verify the regulatory status of any product proposed for their treatment.

The safety profile of deoxycholic acid is considered acceptable when administered by appropriately trained practitioners within the licensed indication, but risks exist and must be clearly communicated during the consent process. Known adverse effects (per the SmPC) include:

• Pain, swelling, bruising, and haematoma formation at the injection site

• Induration (hardening) and temporary numbness, paraesthesia, or hypoaesthesia

• Skin irregularities or contour deformities if injected unevenly

• Skin ulceration or necrosis, particularly if injected too superficially

• Scarring and pigmentation changes

• Infection at injection sites

• Alopecia if injected into hair-bearing areas

For chest injections specifically, practitioners should be aware of the risk of injury to intercostal cutaneous nerves and the consequences of injecting too superficially (skin necrosis) or too deeply (intramuscular injection). The marginal mandibular nerve risk cited in some literature is specific to submental use and is not directly applicable to chest treatment.

The Joint Council for Cosmetic Practitioners (JCCP) and NHS England have both highlighted concerns about the unregulated cosmetic injectables market. Patients are advised to seek treatment only from practitioners who can demonstrate appropriate qualifications, prescribing authority, and indemnity insurance.

Safety-netting advice: Patients should seek prompt medical attention from their GP or an NHS urgent treatment centre if they experience severe or worsening pain, spreading redness or warmth, fever, blistering, skin breakdown, or signs of systemic allergic reaction. Suspected anaphylaxis requires an immediate call to 999.

Suspected adverse reactions to any medicine, including cosmetic injectables, should be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk or via the Yellow Card app.

There is currently no specific NICE guideline addressing fat dissolving injections for gynaecomastia or pseudogynaecomastia, reflecting the limited high-quality clinical evidence available for this indication.

Comparing Injections With Other Treatment Options

Fat dissolving injections are a non-surgical option only for pseudogynaecomastia, but evidence is limited and outcomes less predictable than surgery. Glandular excision remains the gold standard for true gynaecomastia, while watchful waiting or SERMs may be appropriate in selected cases.

When considering treatment for gynaecomastia or pseudogynaecomastia, fat dissolving injections represent just one option within a broader spectrum of approaches. Selecting the most appropriate treatment depends on the underlying cause, the composition of the breast tissue, the severity of the condition, and the patient's overall health and expectations.

Watchful waiting remains appropriate for many cases, particularly in adolescents where spontaneous resolution is common within one to two years. Addressing any underlying cause — such as discontinuing a causative medication under medical supervision, reducing alcohol intake, or managing weight — may also lead to improvement without further intervention. For pseudogynaecomastia specifically, weight management and lifestyle modification are important first-line measures.

Medical management with agents such as tamoxifen or raloxifene (selective oestrogen receptor modulators, SERMs) has been used off-label for true gynaecomastia, particularly in the early, tender phase. These are prescription-only medicines, used outside their licensed indications in this context, and should only be initiated and monitored by a specialist following appropriate clinical work-up. The evidence base for their use is limited.

Surgical options include:

• Liposuction — effective for removing excess fatty tissue and often combined with other techniques

• Glandular excision (subcutaneous mastectomy) — the gold standard for true gynaecomastia involving significant glandular tissue, typically performed under general anaesthetic

• Combination surgery — liposuction alongside glandular excision for mixed presentations

Compared with surgery, fat dissolving injections offer a non-surgical, lower-downtime alternative for carefully selected candidates with predominantly fatty chest tissue. However, it is important to note that high-quality clinical evidence for fat dissolving injections in the male chest is limited. Outcomes are less predictable than surgery, multiple sessions are required, and these injections are not appropriate for glandular gynaecomastia. Surgical correction, whilst more invasive, tends to produce more definitive and consistent results. Patients should have a detailed discussion with a qualified clinician to weigh the benefits and limitations of each approach relative to their individual presentation.

Finding a Qualified Practitioner in the UK

Patients should seek a GMC-, NMC-, GDC-, or GPhC-registered prescriber with specific training in chest anatomy and body contouring injectables. A reputable practitioner will conduct a thorough consultation, obtain written off-label consent, and confirm the regulatory status of the product used.

Choosing a suitably qualified and regulated practitioner is one of the most important steps a patient can take to ensure both safety and satisfactory outcomes. The UK cosmetic injectables sector has faced significant scrutiny in recent years, and ongoing regulatory reform — informed by the 2013 Keogh Review and subsequent NHS England recommendations — has sought to raise standards across the industry.

When seeking a practitioner for fat dissolving injections to the chest, patients should look for the following:

• Prescribing authority: The practitioner should be a registered doctor, dentist, nurse prescriber, or pharmacist prescriber, regulated by the GMC, GDC, NMC, or GPhC respectively

• Relevant training and experience: Specific training in body contouring injectables and chest anatomy is essential

• Membership of a recognised professional body: Organisations such as the British College of Aesthetic Medicine (BCAM), the Aesthetic Complications Expert (ACE) Group, or registration with the JCCP provide additional assurance

• Transparent consultation process: A reputable practitioner will conduct a thorough medical history, assess tissue composition (with imaging if indicated), discuss realistic expectations, and obtain written informed consent — including explicit off-label consent if the product is being used outside its licensed indication, or if an unlicensed product is proposed

• Product transparency: Patients should ask which specific product is being used, whether it holds a UK marketing authorisation, and what its licensed indication is

• Emergency preparedness: The practitioner should have protocols in place for managing adverse events, including an anaphylaxis kit (adrenaline auto-injector), infection management protocols, and appropriate analgesia. Note that hyaluronidase is not relevant to deoxycholic acid complications and should not be cited as a reversal agent for fat dissolving injections

• CQC registration: Where the treatment is provided as part of a regulated activity, practitioners and clinics may be subject to Care Quality Commission (CQC) oversight

Patients are advised to be cautious of practitioners offering treatments at unusually low prices, those who do not conduct a pre-treatment consultation, or those operating outside of a clinical environment. The NHS does not routinely fund fat dissolving injections for gynaecomastia or pseudogynaecomastia, as this is considered a cosmetic procedure. If there is any uncertainty about whether chest enlargement has an underlying medical cause, a GP referral for assessment prior to any cosmetic treatment is strongly recommended.

Any suspected adverse reactions following treatment should be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

Frequently Asked Questions